Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Mycosis Fungoides 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Waldenstrom Macroglobulinemia 1Neoplasms 1Neoplasm Metastasis 1Mycoses 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

Rituximab 24Lenalidomide 12Cyclophosphamide 12fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 10Mycophenolic Acid 6Cyclosporine 6Whole-Body Irradiation 5Radiotherapy 5Filgrastim 5ibritumomab tiuxetan 4Indium 4Etoposide 4romidepsin 3Sirolimus 3Prednisone 3Pentostatin 3Methotrexate 3Melphalan 3In Situ Hybridization, Fluorescence 3Gene Expression Profiling 3Everolimus 3Busulfan 3Bortezomib 3Bendamustine Hydrochloride 3zanubrutinib 2venetoclax 2veltuzumab 2temsirolimus 2obinutuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, B-Cell, Marginal Zone × ProMune × Clear all
NCT00438880 2016-02-04

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Mayo Clinic

Phase 1/2 Completed
38 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡